Mid Cap Bearish Stocks: Celldex Therapeutics (NASDAQ:CLDX), Qiwi PLC (NASDAQ:QIWI), Nu Skin Enterprises (NYSE:NUS), Darden Restaurants (NYSE:DRI)

Celldex Therapeutics, Inc. (Nasdaq:CLDX) reported business and financial highlights for the fourth quarter and year ended December 31, 2013 and outlined the Company’s major clinical development goals for 2014.This past year was transformational for Celldex as we continued to make strides in cultivating one of the most robust, well-staged pipelines in immuno-oncology,” said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics. “We enter 2014 with five candidates in the clinic, including rindopepimut and glembatumumab vedotin in registration studies. By year-end, we anticipate the initiation of four new Celldex-sponsored clinical trials and several investigator-sponsored studies, including multiple combination regimens. These combination studies are designed to address what we believe is the next great opportunity for the immuno-oncology field—further unlocking the power of the immune system to deliver the greatest benefit to the largest population of patients possible. With last year’s successful financing of the Company and current cash projected to fund our planned activities through 2016, we look forward to what we believe will be an exceptionally productive year Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock opened at $27.36 in last session, and closed at $26.28, while the day range of CLDX stock is $25.76-$27.73.The stock showed a negative weekly performance of -16.68%.

Qiwi PLC (NASDAQ:QIWI) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 1,162,868 shares, a growth of 112.0% from the January 15th total of 548,649 shares, Analyst Ratings Network reports. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,109,546 shares, the days-to-cover ratio is presently 1.0 days. Qiwi PLC (NASDAQ:QIWI) stock opened at $41.51, in last session and closed at $38.82, by loosed -16.75%. The 52 week range was $14.51-$59.24.Company’s market capitalization is $3.55 billion.

Nu Skin Enterprises Inc. (NYSE: NUS) reported Q4 EPS of $2.02, $0.03 better than the analyst estimate of $1.99. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.07 billion. Nu Skin Enterprises, Inc. (NYSE:NUS) stock loosed -10.67% and finished the last session at $74.61.The EPS of the stock remained 4.89.Company’s market capitalization is $4.44 billion.

Darden Restaurants Inc. (NYSE:DRI) updated its third quarter earnings guidance on Monday. The company provided earnings per share guidance of $0.82 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.94, American Banking and Market News reports. Darden Restaurants, Inc. (NYSE:DRI) stock opened the session at $49.18, and closed the session at $48.33. The 52 week range of the DRI stock remained $44.78-$55.25 and the day range was $48.07-$49.50.